全文获取类型
收费全文 | 164014篇 |
免费 | 15788篇 |
国内免费 | 7522篇 |
专业分类
耳鼻咽喉 | 2279篇 |
儿科学 | 3751篇 |
妇产科学 | 1817篇 |
基础医学 | 30018篇 |
口腔科学 | 5328篇 |
临床医学 | 12619篇 |
内科学 | 22042篇 |
皮肤病学 | 4425篇 |
神经病学 | 9100篇 |
特种医学 | 3631篇 |
外国民族医学 | 118篇 |
外科学 | 14363篇 |
综合类 | 25712篇 |
现状与发展 | 48篇 |
预防医学 | 4300篇 |
眼科学 | 3458篇 |
药学 | 12715篇 |
25篇 | |
中国医学 | 5064篇 |
肿瘤学 | 26511篇 |
出版年
2024年 | 131篇 |
2023年 | 2289篇 |
2022年 | 2889篇 |
2021年 | 5570篇 |
2020年 | 5297篇 |
2019年 | 5171篇 |
2018年 | 5358篇 |
2017年 | 5662篇 |
2016年 | 5929篇 |
2015年 | 6757篇 |
2014年 | 9829篇 |
2013年 | 10891篇 |
2012年 | 9449篇 |
2011年 | 10586篇 |
2010年 | 8803篇 |
2009年 | 8438篇 |
2008年 | 8883篇 |
2007年 | 9114篇 |
2006年 | 8281篇 |
2005年 | 7613篇 |
2004年 | 6750篇 |
2003年 | 5858篇 |
2002年 | 4800篇 |
2001年 | 4123篇 |
2000年 | 3388篇 |
1999年 | 2955篇 |
1998年 | 2428篇 |
1997年 | 2383篇 |
1996年 | 2054篇 |
1995年 | 2079篇 |
1994年 | 1837篇 |
1993年 | 1531篇 |
1992年 | 1244篇 |
1991年 | 1171篇 |
1990年 | 899篇 |
1989年 | 842篇 |
1988年 | 788篇 |
1987年 | 628篇 |
1986年 | 584篇 |
1985年 | 773篇 |
1984年 | 691篇 |
1983年 | 482篇 |
1982年 | 508篇 |
1981年 | 402篇 |
1980年 | 340篇 |
1979年 | 254篇 |
1978年 | 178篇 |
1977年 | 139篇 |
1976年 | 103篇 |
1975年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
61.
《Transfusion and apheresis science》2022,61(5):103447
BackgroundPatients' inflammatory history is an important factor underlying red blood cell (RBC) alloimmunization, which is a frequent transfusion complication among individuals with sickle cell disease (SCD). HLA-G has been associated with different inflammatory and auto - immune diseases. Our goal was to verify whether the HLA-G + 3142 C>G and 14-bp Ins/Del variations are associated with RBC antibody development among SCD patients.MethodsThis was a single-center case-control study. SCD patients were randomly selected for the study and divided into two groups: ‘Alloimmunized’ and ‘Nonalloimmunized’ depending on the presence of irregular antibodies. The ‘Alloimmunized’group was further divided into two subgroups according to the presence of only antibodies against the Rh and Kell blood group systems or the existence of antibodies to antigens of the other blood group systems.ResultsA total of 213 patients were included in the study (110 alloimmunized and 103 non-alloimmunized). The ‘Alloimmunized’ and ‘Non-alloimmunized’ groups did not differ statistically regarding the HLA-G + 14 bp Ins/Del ( p = 0.494) and + 3142 C>G ( p = 0.334). Individuals who had only antibodies against the Rh and Kell antigens had a frequency of HLA-G + 3142GG genotype almost twice as high compared to the groupwith antibodies against less immunogenic antigens ( p = 0.043).ConclusionsThe genotype frequency of HLA-G + 3142 C>G differs among alloimmunized SCD patients, depending on the presence of antibodies against low immunogenic RBC antigens. This highlights a possible role played by the HLA-G molecule in the RBC alloimmunization process. 相似文献
62.
63.
ObjectivesMap regional lymph node metastases for lateralized oral cavity squamous cell carcinoma (OCSCC) and evaluate factors associated with regional metastases and recurrence.Materials and methodsRetrospective cohort study of 715 patients with lateralized OCSCC surgically treated in 1997–2011. Analysis was performed using log-rank, Kaplan-Meier, and multivariable logistic and Cox regression.ResultsRegional metastases were identified in ipsilateral levels IIA (24%), IB (18%), III (13%), V (9%), IV (7%), IA (2%) and IIB (1%) and the contralateral neck (3%). Lymphovascular invasion (LVI) (Hazard Ratio [HR] 2.2, 95% Confidence Interval [CI] 1.2–3.9) and T category (T3 vs. T1: HR 4.1, 95% CI 1.9–9.3; T4 vs. T1: HR 2.3, 95% CI 1.2–4.3) were associated with regional metastases. Most (71%) isolated regional metastatic recurrences were in undissected levels of the neck, including 58% in levels IV and V. Tumors of the hard palate (HR 4.3, 95% CI 1.2–16.1), upper alveolus (HR 3.2, 95% CI 1.0–4.7) or with LVI (HR 2.0, 95% CI 1.0–3.9) were associated with isolated regional recurrence. For upper alveolar/hard palate tumors, depth of invasion (DOI) ≥4 mm (P = .003) and LVI (P = .04) were associated with regional metastases.ConclusionsFor lateralized OCSCC, elective neck dissection of level IIB or the contralateral neck may rarely be needed, but additional surgical or radiation treatment of levels IV and V may be considered based on patient risk factors, including T category 3–4 or LVI. For upper alveolar/hard palate tumors, DOI ≥4 mm is an appropriate threshold for elective neck dissection. 相似文献
64.
65.
66.
67.
ObjectivesTo determine the anti-inflammatory effects of green tea catechins in immortalized human gingival epithelial cells (Ca9-22) stimulated with Porphyromonas gulae lipopolysaccharide (LPS).MethodsCa9-22 cells were incubated with P. gulae LPS (10 μg/ml) with or without green tea catechins, epigallocatechin-3-gallate (EGCg), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epicatechin (EC) (each at 50 μM), for 6 or 24 h. Real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay were used to determine the induction of cyclooxygenase 2 (COX2), tumor necrosis factor alpha (TNF-ɑ), interleukin 6 (IL-6), and IL-8. Furthermore, the expression of toll-like receptors (TLRs) 2 and 4 was examined using real-time PCR and western blotting analysis, and phosphorylation of the p38 and ERK1/2 was examined using western blotting analysis.ResultsAt the mRNA and protein levels, EGCg, EGC, ECG, and EC were found to significantly inhibit COX2, TNF-ɑ, IL-6, and IL-8. Furthermore, the levels of ERK1/2 and p38 phosphorylation induced by P. gulae LPS were decreased following the addition of each of the catechins, as well as TLR2 and 4 mRNA and protein.ConclusionsThese findings indicate that green tea catechins are potent inhibitors of in?ammatory responses induced by P. gulae LPS, and may also be useful for prevention and/or attenuation of periodontitis. 相似文献
68.
1文献来源Jabbour SK,Lee KH,Frost N,et al.Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable,locally advanced,stageⅢnon?small cell lung cancer.The phase 2 KEYNOTE?799 nonrandomized trial[J].JAMA Oncol,2021,7(9):1-9. 相似文献
69.
70.